Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 2/20 | 0.45 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.45 |
| ▸ | CPT2 | P23786 | 1/20 | 0.43 |
| ▸ | HASPIN | Q8TF76 | 5/20 | 0.43 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | SPR | P35270 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5458138 | 0.88 | HASPIN (0.51) | CPT1ACPT1BCPT2HASPINIDH1 | |
| SCHEMBL15687602 | 0.88 | HASPIN (0.50) | CPT1ACPT1BCPT2HASPINIDH1 | |
| SCHEMBL1993367 | 0.86 | HASPIN (0.47) | CPT1ACPT1BCPT2HASPINSNCA | |
| SCHEMBL5456611 | 0.84 | POLB (0.45) | CPT1ACPT1BCPT2IDH1 | |
| SCHEMBL29202630 | 0.82 | IDH1 (0.45) | CPT1ACPT1BCPT2HASPINIDH1 | |
| SCHEMBL30888890 | 0.82 | IDH1 (0.45) | CPT1ACPT1BCPT2HASPINIDH1 | |
| SCHEMBL4249517 | 0.82 | HASPIN (0.39) | CPT1ACPT1BCPT2HASPINADRB2 | |
| SCHEMBL3674759 | 0.82 | PLA2G4A (0.59) | CPT1ACPT1BCPT2 | |
| SCHEMBL5467817 | 0.82 | CPT1A (0.57) | CPT1ACPT1BCPT2HASPIN | |
| SCHEMBL2879361 | 0.80 | GPR84 (0.56) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371281-B2 | Indole derivatives as inhibitors of histone deacetylase | PHARMACYCLICS LLC (US) | 2016-06-21 | — | — | US | disclosed |
| US-20150299119-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS LLC | 2015-10-22 | — | — | US | disclosed |
| US-8900565-B2 | Indole derivatives as inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130156727-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8338416-B2 | Indole derivatives as inhibitors of histone deacetylase | PHARMACYLICS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20070281934-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299119-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | HDAC8, HDAC1, HDAC2 | CPT1A 314/4885CPT1B 1322/4885CPT2 825/4885 |
| US-20070281934-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | HDAC8, HDAC1, HDAC2 | CPT1A 314/4885CPT1B 1322/4885CPT2 825/4885 |
| US-20130156727-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | HDAC8, HDAC1, HDAC2 | CPT1A 314/4885CPT1B 1322/4885CPT2 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.